Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

Education and training in the use and operation of medical and surgical equipment, apparatus and appliances and instruments, and consultation relating to the selection and purchase thereof and use in medical care, medical therapy and surgery. Medical research services. Providing medical information, consultancy and advisory services; professional consultation in the field of medical and surgical equipment, apparatus, appliance and instruments; consultation on medical care, medical therapy and surgery; consultation services, namely, providing medical information to medical professionals to assist in the diagnosis and treatment of patients; medical consultation with physicians regarding the use of medical apparatus for treatment of patients; technical consultation in the field of medical and surgical equipment, apparatus, appliances and instruments, namely, consultation regarding the selection and purchase thereof, and the use in providing medical care, medical therapy and surgery; providing a patient support program, namely, providing medical information to patients evaluating therapeutic treatment options; providing medical information to patients in the field of surgery preparation; maintaining patient medical records and files in preparation for surgery; providing medical advisory and consultancy services concerning medical coding and medical reimbursement; providing online medical evaluation services, namely, functional assessment program for patients who are about to receive medical treatment services for purposes of guiding treatment and assessing program effectiveness; home health care services in the nature of interactive medical care monitoring for patients; managed healthcare services, namely, providing disease management programs to others; providing medical information and healthcare information accessible to healthcare providers including case studies, peer-reviewed journal articles and references, via an on-line computer database; providing medical information for medical professionals via monitoring devices for purposes of monitoring and diagnosing medical conditions via a website.

Abrégé

The present invention provides a novel pyrimidine compound represented by Formula [I] and a salt thereof: The present invention provides a novel pyrimidine compound represented by Formula [I] and a salt thereof: The present invention provides a novel pyrimidine compound represented by Formula [I] and a salt thereof: [in the formula, the symbols are as defined in the specification], which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.

Classes IPC  ?

• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• A61P 25/08 - AntiépileptiquesAnticonvulsivants
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07F 7/08 - Composés comportant une ou plusieurs liaisons C—Si

Abrégé

Provided is an orally administered substance provided with a magnetic marker that can be detected easily by a magnetic sensor even with a small amount applied. The orally administered substance contains a composition for oral administration and a magnetic marker provided on the composition for oral administration. The magnetic marker contains a magnetic powder and a binder and has a squareness ratio of 0.40 or more.

Classes IPC  ?

• A61K 47/02 - Composés inorganiques
• A61J 3/06 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration la forme de pilules, tablettes ou pastilles
• A61K 9/44 - Pilules, pastilles ou comprimés avec des impressions, reliefs, rainures ou perforations
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61K 47/38 - CelluloseSes dérivés
• C09D 11/00 - Encres

Abrégé

The present invention addresses the problem of providing: a method for reprogramming differentiated hair follicle mesenchymal cells to produce stem or progenitor cells of the hair follicle mesenchymal cells; and a composition for preventing or ameliorating the thinning or graying of hair by using a secretion factor derived from the cells.　A method for producing hair follicle mesenchymal stem or progenitor cells which solves the problem of the present invention is characterized by comprising bringing hair follicle mesenchymal cells into contact with a ROCK inhibitor in vitro. A composition that solves the problem of the present invention is characterized by containing an exosome or microRNA derived from the cells, and is capable of suppressing losing or graying of hair.

Classes IPC  ?

• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux
• A61K 8/60 - SucresLeurs dérivés
• A61K 8/98 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés d'origine animale
• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
• A61K 35/36 - PeauSystème pileuxOnglesGlandes sébacéesCérumenÉpidermeCellules épithélialesKératinocytesCellules de LangerhansCellules ectodermiques
• A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• A61Q 7/00 - Préparations pour modifier la pousse des cheveux ou des poils
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

Provided is a novel compound serving as an analogue to be removed from API or a preparation. Further provided is a reference standard of an analogue for use in the quality control of a medicament. Analogue 1: 3-ethyl-4-{4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3,3′-di(propan-2-yl)-1′H-[1,4′-bipyrazolo[3,4-b]pyridin]-1′-yl}benzamide. Analogue 2: 3-ethyl-4-fluorobenzamide. Analogue 3: N-[1-(4-carbamoyl-2-ethylphenyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-3-ethyl-4-{4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide. Analogue 4: 3-ethyl-4-{14-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-13,23,33-tri(propan-2-yl)-31H-[11,24:21,34-terpyrazolo[3,4-b]pyridin]-31-yl}benzamide. Analogue 5: 4,4′-(1H,1′H-[4,4′-biimidazole]-1,1′-diylbis{[3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-4,1-diyl]})bis(3-ethylbenzamide). Analogue 6: 4-{4,6-bis[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl }-3-ethylbenzonitrile. Analogue 7: 4-{4,6-bis[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl }-3-ethylbenzamide. Analogue 8: 4-[4-ethoxy-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl]-3-ethylbenzamide. Analogue 9: 3-ethyl-4-[4-methoxy-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl]benzamide.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• C07C 233/65 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant les atomes d'azote des groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone de radicaux hydrocarbonés non substitués
• C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou

Abrégé

Provided is a novel compound useful for, e.g., comprehensive analysis of cell surface proteins. Disclosed is a functional compound or a salt thereof in which a tyrosine residue reaction site R is linked to a protein purification tag site Tag via a spacer S. The tyrosine residue reaction site R is a group represented by formula (1). (In the formula, * denotes a bond with a spacer S, and R1and R2 are each independently selected from the group consisting of H, alkyl which optionally be substituted with one or more substituents, aryl which optionally be substituted with one or more substituents, and heteroaryl which optionally be substituted with one or more substituents.)

Classes IPC  ?

• C07D 495/04 - Systèmes condensés en ortho
• C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07K 1/13 - Marquage de peptides
• C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective

Produits et services

Dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; lacteal flour for babies; nutritional supplements consisting primarily of proteins, fats and/or carbohydrates in liquid, jelly, gel or powder form; nutritional supplements; dietary supplements for human beings; dietary supplements for human beings, namely, dietary supplement drinks, dietary supplement in liquid, jelly, gel or powder form, and dietary supplement drink mixes; nutritional supplements, namely, powdered nutritional supplement drink mix.

Produits et services

Dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; lacteal flour for babies; nutritional supplements consisting primarily of proteins, fats and/or carbohydrates in liquid, jelly, gel or powder form; nutritional supplements; dietary supplements for human beings; dietary supplements for human beings, namely, dietary supplement drinks, dietary supplement in liquid, jelly, gel or powder form, and dietary supplement drink mixes; nutritional supplements, namely, powdered nutritional supplement drink mix. Jellies for food, other than confectionery; jellies, jams, compotes; gelatine for food; meat jellies; fish jellies; fruit jellies, other than confectionery; vegetable jellies; kanten [dried pieces of agar jelly]; meat jellies containing collagen peptides; fish jellies containing collagen peptides; fruit jellies, other than confectionery, containing collagen peptides; vegetable jellies containing collagen peptides; protein milk; soya milk in jelly; soya-based snack foods; milk-based beverages flavored with coffee; milk-based beverages containing fruit juice; fruit-based, vegetable-based, bean-based or nut-based snacks. Puddings; jellies [confectionery]; bavarian creams; confectionery; bread and buns; porridge; processed grains; boxed lunches consisting of rice, with added meat, fish or vegetables; instant confectionery mixes; ice cream mixes; sherbet mixes; coffee; cocoa; tea; sweets; artificial coffee; pastries; processed cereals; preparations made from rice; wheat, processed; ready-to-eat cereals; gluten-free cereal products; cereal bars. Soft drinks; fruit juices; vegetable juices [beverages]; whey beverages; beer; extracts of hops for making beer; fruit and vegetable smoothies; non-alcoholic beverages for nutritional purposes; non-alcoholic beverages; smoothies; energy drinks; isotonic beverages; soft drinks in jelly [beverages]; fruit juices in jelly [beverages]; vegetable juices in jelly [beverages]; whey beverages in jelly; isotonic beverages in jelly; concentrates, syrups and powders used in the preparation of soft drinks; syrups and other non-alcoholic preparations for making beverages; powders used in the preparation of non-alcoholic beverages for nutritional purposes; powders used in the preparation of fruit-based beverages; syrups for beverages; soft drinks in powder form; fruit juices in powder form; vegetable juices in powder form [beverages]; whey beverages in powder form; isotonic beverages in powder form; non-alcoholic beverages, other than for dietary or medical purposes; powder used in the preparation of non-alcoholic beverages, other than for dietary or medical purposes; soft drink mixes; non-carbonated soft drinks; coffee-flavored soft drinks; fruit-flavored soft drinks; vitamin fortified soft drinks; sports drinks.

Produits et services

Pharmaceutical preparations; medicinal drinks; lacteal flour for babies; nutritional supplements; dietary supplements; food supplements; nutritional and dietary supplements formed and packaged as bars; dietary supplement drinks; dietary supplement drink mixes; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies. Fruit-based snack foods; vegetable-based snack foods; bean-based snack foods; nut-based snack foods; edible oils and fats; milk products; milk beverages, milk predominating; lactic acid drinks; lactic acid bacteria drinks; frozen vegetables; frozen fruits; charcuterie; processed seafood products; processed vegetables and fruits; soya milk; pre-cooked curry stew, stew and soup mixes; instant soup; pre-cooked soup; preserved pulses; soya beans, preserved, for food. Tea; coffee; cocoa; sweets; cereal-based snack foods; confectionery; pastries; chocolate; caramels; candies; chewing gum; nougat; cookies; crackers; biscuits; rusks; bread; sandwiches; hamburger sandwiches; pizzas; hot dog sandwiches; meat pies; seasonings; soya sauce; spices; processed cereals; cereal bars; instant noodles; chocolate spread; instant confectionery mixes; flour; soya flour. Non-alcoholic beverages; soft drinks; sports drinks; sports drinks containing electrolytes; isotonic beverages; jelly drinks; powdered sports drink mixes; fruit juices; vegetable juices [beverages]; whey beverages; beer.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations; medicinal drinks; lacteal flour for babies; nutritional supplements; dietary supplements; food supplements; nutritional and dietary supplements formed and packaged as bars; dietary supplement drinks; dietary supplement drink mixes; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies.

Abrégé

The objective of the present invention is to provide a freeze-dried powdered green tea beverage having excellent dispersibility in water, and a method for producing the same. This freeze-dried powdered green tea beverage comprising a freeze-dried product of a liquid composition containing, in water, (A) powdered green tea, (B) water-soluble dietary fiber, and (C) (C1) an amylolytic enzyme-treated product of cereal grains and/or (C2) animal milk has excellent dispersibility in water.

Classes IPC  ?

• A23L 2/00 - Boissons non alcooliséesCompositions sèches ou concentrés pour les fabriquer Leur préparation ou leur traitement
• A23F 3/32 - Agglomération, mise en flocons ou en tablettes
• A23L 2/38 - Autres boissons non alcoolisées

Produits et services

Dietary and nutritional supplements; Vitamin and mineral supplements On-line ordering services featuring vitamins, minerals, and nutritional and dietary supplements

Produits et services

Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; infusion solutions for medical purposes; pharmaceutical preparations.

Abrégé

The present invention relates to tetrahydropyrazolopyridine derivatives having AAK1 inhibitory activity.

Classes IPC  ?

• C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 25/16 - Antiparkinsoniens
• A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 31/12 - Antiviraux

Produits et services

Pharmaceutical preparations; diagnostic preparations for medical purposes; diagnostic reagents for medical use. Providing medical information; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; pathological testing for diagnostic or treatment purposes.

Abrégé

The present disclosure is directed to methods of dispersing injectable preparations comprising aripiprazole or a salt thereof. Methods of enhancing slidability of containers comprising long-acting injectable preparations comprising aripiprazole or a salt thereof, the methods comprising dispersing ingredients comprised in the preparations before administration, aripiprazole injectable preparations to be administered after the dispersion, methods of administration thereof, and use thereof are provided.

Classes IPC  ?

• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/02 - Composés inorganiques
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/38 - CelluloseSes dérivés
• A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage

Abrégé

Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.

Classes IPC  ?

• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole

Abrégé

The present invention relates to a microorganism belonging to the genus Akkermansia, having a 16S rRNA gene comprising a nucleotide sequence etc. having homology of more than 98.0% to a nucleotide sequence set forth in SEQ ID NO: 3, having NOD2 agonistic activity, having assimilability to D-mannitol, being a Gram-negative, anaerobic bacterium with a spherical to short rod-shaped form, being negative in an oxidase test, and being positive in a catalase test, and a microorganism for activating NOD2, activating immunity, etc., comprising the microorganism as an active ingredient.

Classes IPC  ?

• C12N 1/20 - BactériesLeurs milieux de culture
• A61K 35/741 - Probiotiques
• C12R 1/01 - Bactéries ou actinomycètes

Abrégé

Provided is a pharmaceutical composition containing compound 1, the pharmaceutical composition having excellent disintegratability and bioavailability. The pharmaceutical composition comprises: a granulated product containing 3-ethyl-4-{4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide or a pharmaceutically acceptable salt thereof; and crystalline cellulose, and has a disintegration time of within 360 seconds in a coated tablet form.

Classes IPC  ?

• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/28 - DragéesPilules ou comprimés avec revêtements
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline

Produits et services

Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; pharmaceutical preparations for the treatment of schizophrenia; pharmaceutical preparations for the treatment of cognitive disorders; pharmaceutical preparations for the treatment of major depressive disorder; pharmaceutical preparations for the treatment of generalized anxiety disorder.

Produits et services

Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; pharmaceutical preparations for the treatment of schizophrenia; pharmaceutical preparations for the treatment of cognitive disorders; pharmaceutical preparations for the treatment of major depressive disorder; pharmaceutical preparations for the treatment of generalized anxiety disorder.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Abrégé

A method for detecting conjunctival diseases such as conjunctival MALT lymphoma, and an aging biomarker that serves as an indicator of the aging state of a subject are provided. The method for detecting conjunctival diseases comprises a step of comparing a microbial community structure of a microbiota in an ocular surface tissue specimen sampled from a healthy person with a microbial community structure of a microbiota in an ocular surface tissue specimen sampled from a subject to determine that the ocular surface tissue specimen of the subject has an indication of the conjunctival diseases. The aging biomarker comprises bacterial species which belongs to the Corynebacteriaceae family or the Propionibacteriales family in an ocular surface tissue.

Classes IPC  ?

• C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
• C12Q 1/06 - Détermination quantitative

Abrégé

Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10 ?m, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g., a high shear pulverizing machine, a dispersion machine that applies shear force to a material to be processed, a colloid mill, an ultrasonic dispersion machine, or a high-pressure jet type emulsifying dispersion machine to form a secondary suspension; and (c) subjecting the secondary suspension to second pulverization using e.g., a high pressure jet type emulsifying dispersion machine to form a sterile final suspension; and a method for producing a freeze dried formulation from the aripiprazole suspension.

Classes IPC  ?

• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 9/10 - DispersionsÉmulsions
• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
• A61K 47/38 - CelluloseSes dérivés

Abrégé

The present invention provides a method for treating various diseases with a novel heterocyclic compound represented by Formula [I] and a salt thereof: The present invention provides a method for treating various diseases with a novel heterocyclic compound represented by Formula [I] and a salt thereof: The present invention provides a method for treating various diseases with a novel heterocyclic compound represented by Formula [I] and a salt thereof: wherein the symbols are as defined in the specification, which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.

Classes IPC  ?

• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• A61P 25/08 - AntiépileptiquesAnticonvulsivants
• C07D 239/34 - Un atome d'oxygène
• C07D 239/47 - Un atome d'azote et un atome d'oxygène ou de soufre, p. ex. cytosine
• C07D 239/54 - Deux atomes d'oxygène liés par une liaison double ou sous forme de radicaux hydroxyle non substitués
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 471/04 - Systèmes condensés en ortho
• C07D 487/04 - Systèmes condensés en ortho

Abrégé

The purpose of the present invention is to provide a viscoelastic composition having excellent operability, which is suitable for use in securing the field of view of an endoscope when opaque dark-colored liquid accumulates inside a canal and obstructs the field of view of the endoscope, the viscoelastic composition securing the field of view by pushing the liquid aside, and to provide a method for securing the field of view of an endoscope using the viscoelastic composition. The viscoelastic composition for securing the field of view of an endoscope comprises a substance having viscoelastic properties and water, preferably has a hardness of 550 N/m2 or less, a viscosity (25° C.) of 200 to 2,000 mPa·s, and a loss tangent of 0.6 or less, and more preferably has an electrical conductivity of 250 μS/cm or less. The method for securing the field of view of an endoscope comprises feeding the viscoelastic composition from a proximal part of the endoscope, through a channel, into a distal part of the endoscope.

Classes IPC  ?

• A61L 31/04 - Matériaux macromoléculaires
• A61B 1/015 - Commande de l'alimentation en fluide ou de l'évacuation de fluide
• A61B 1/12 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec système de refroidissement ou de rinçage
• A61L 29/02 - Matériaux inorganiques
• A61L 29/04 - Matériaux macromoléculaires
• A61L 29/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
• A61L 31/02 - Matériaux inorganiques
• A61L 31/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques

Produits et services

(1) Medicinal drinks; lacteal flour for babies; nutritional supplements; dietary supplements; food supplements; nutritional and dietary supplements formed and packaged as bars; dietary supplement drinks; dietary supplement drink mixes; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies. (2) Fruit-based snack foods; vegetable-based snack foods; bean-based snack foods; nut-based snack foods; edible oils and fats; milk products; milk beverages, milk predominating; lactic acid drinks; lactic acid bacteria drinks; frozen vegetables; frozen fruits; charcuterie; processed seafood products; processed vegetables and fruits; soya milk; pre-cooked curry stew, stew and soup mixes; instant soup; pre-cooked soup; preserved pulses; soya beans, preserved, for food. (3) Tea; coffee; cocoa; sweets; cereal-based snack foods; confectionery; pastries; chocolate; caramels; candies; chewing gum; nougat; cookies; crackers; biscuits; rusks; bread; sandwiches; hamburger sandwiches; pizzas; hot dog sandwiches; meat pies; seasonings; soya sauce; spices; processed cereals; cereal bars; instant noodles; chocolate spread; instant confectionery mixes; flour; soya flour. (4) Non-alcoholic beverages; soft drinks; sports drinks; sports drinks containing electrolytes; isotonic beverages; jelly drinks; powdered sports drink mixes; fruit juices; vegetable juices [beverages]; whey beverages; beer.

Produits et services

(1) Medicinal drinks; lacteal flour for babies; nutritional supplements; dietary supplements; food supplements; nutritional and dietary supplements formed and packaged as bars; dietary supplement drinks; dietary supplement drink mixes; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies.

Produits et services

Pharmaceutical preparations.

Produits et services

Pharmaceutical preparations.

Produits et services

(1) Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the treatment of attention deficit hyperactivity disorder; pharmaceutical preparations for the prevention and treatment of smoking habits and addictions.

Abrégé

The invention provides biomarkers to predict effective treatment of cancer using an IAP antagonist. Identifying one or more of the identified biomarkers in a cancer patient allows a determination to be made whether the patient's cancer is likely to be successfully treated using an IAP antagonist. Accordingly, the invention relates generally to a companion diagnostic for IAP antagonist therapy. In particular, the biomarkers include IL-2Rα, IL-6r, CRP, EPO, CD27, CD40, TN-C, IL-18, PLGF, TNFrl and MCP-4.

Classes IPC  ?

• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes

Produits et services

On-line retail store services featuring vitamins, minerals, and nutritional and dietary supplements Vitamin and mineral supplements; Dietary and nutritional supplements

Abrégé

Provided is a composition in the form of a suspension of submicron particles which is useful as a composition comprising Quabodepistat or a salt thereof, etc. Disclosed, as one example of the composition, is a composition comprising at least one selected from the group consisting of Quabodepistat, salts and co-crystals thereof, and solvates thereof. The composition further comprises a suspending agent and a dispersion medium, and takes the form of a suspension of submicron particles.

Classes IPC  ?

• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
• A61K 9/10 - DispersionsÉmulsions
• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61P 31/04 - Agents antibactériens
• A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose

Abrégé

Provided is a composition in the form of a suspension of submicron particles, which is useful as a composition containing delamanid or a salt thereof. Disclosed as one embodiment of the composition is a composition which contains delamanid or a salt thereof. The composition contains a suspending agent and a dispersion medium and is in the form of a suspension of submicron particles. The suspending agent comprises at least one member selected from the group consisting of Poloxamers and D-α-tocopherol polyethylene glycol succinates.

Classes IPC  ?

• A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
• A61K 9/10 - DispersionsÉmulsions
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose

Abrégé

This method for producing mesenchymal cells of the ventral hindgut mesoderm comprises: culturing pluripotent stem cells in an induction medium A containing a TGF-β inhibitor, a Wnt agonist, and a fibroblast growth factor to induce differentiation into epiblast-like cells; culturing the epiblast-like cells in an induction medium B containing a Wnt agonist, a fibroblast growth factor, and retinoic acid to induce differentiation into caudal epiblast-like cells; culturing the caudal epiblast-like cells in an induction medium C containing a Wnt agonist, a bone morphogenetic protein, and a TGF-β family member to induce differentiation into posterior primitive streak cells; and culturing the posterior primitive streak cells in an induction medium D containing a Wnt agonist, a fibroblast growth factor, a bone morphogenetic protein, and a hedgehog signaling agonist to induce differentiation into mesenchymal cells of the ventral hindgut mesoderm.

Classes IPC  ?

• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
• A61K 35/22 - UrineAppareil urinaire, p. ex. rein ou vessieCellules mésangiales intraglomérulairesCellules mésenchymateuses rénalesGlande surrénale
• A61P 13/10 - Médicaments pour le traitement des troubles du système urinaire de la vessie
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet
• G01N 33/15 - Préparations médicinales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

Provided is a crystal of a compound having EGFR inhibition ability or a salt thereof, said crystal being excellent in one or more characteristics of stability, hygroscopicity and oral absorbability. One aspect of the present invention provides a crystal form of N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptan-1-yl)-5-methylpyrazine-2-carboxamide the diffraction angle (2θ±0.2°) of which has a peak at a preset angle in the X-ray powder diffraction spectrum.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles

Abrégé

Provided is a composition in the form of a suspension of microparticles, which is useful as a composition comprising quabodepistat, a salt thereof, or the like. Disclosed as one example of the composition is a composition comprising at least one selected from quabodepistat, a salt thereof, a cocrystal thereof, and solvates of these, wherein the composition contains a suspending agent and a dispersion medium and is in the form of a suspension of microparticles.

Classes IPC  ?

• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
• A61K 9/10 - DispersionsÉmulsions
• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/38 - CelluloseSes dérivés
• A61P 31/04 - Agents antibactériens
• A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose

Abrégé

Methods of using centanafadine in treating ADHD and reducing ADHD symptoms are disclosed.

Classes IPC  ?

• A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

The present invention aims to provide a method for evaluating dementia and a composition for preventing or treating deterioration in brain function, or for maintaining or improving brain function, and compared the gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease. As a result, gut microorganisms were selected, such as microorganisms belonging to the genus Faecalibacterium, that are associated with cognitive function. Furthermore it was revealed that Faecalibacterium prausnitzii, possessing specific DNA, exhibited an improvement effect against brain function deterioration, such as learning and memory disorders.

Classes IPC  ?

• A61K 35/74 - Bactéries
• A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The present invention provides a method for producing a compound represented by formula (I) suitable for mass synthesis as API. Provided according to one aspect of the present invention is a method for producing a compound represented by formula (I) or a salt thereof, the method including deprotecting a protecting group represented by R1 in formula (II) under basic conditions to thereby form a compound represented by formula (I) or a salt thereof. The present invention provides a method for producing a compound represented by formula (I) suitable for mass synthesis as API. Provided according to one aspect of the present invention is a method for producing a compound represented by formula (I) or a salt thereof, the method including deprotecting a protecting group represented by R1 in formula (II) under basic conditions to thereby form a compound represented by formula (I) or a salt thereof.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho

Abrégé

Disclosed are compounds, or salts thereof, with sortilin-binding inhibitory activity, medical use thereof for treating, preventing, and/or diagnosing diseases associated with sortilin ligands, and methods of preparing said compounds, or salts thereof. Provided is a compound of formula (I), or a salt thereof, wherein R1is H, etc.; R21-6 1-6 alkyl, etc.; R322 or O; R41-6 1-6 alkyl; and Ring A is optionally substituted partially unsaturated or unsaturated 7- to 15-membered bicyclic or tricyclic heterocyclyl.

Classes IPC  ?

• C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
• C07D 471/04 - Systèmes condensés en ortho
• C07D 487/04 - Systèmes condensés en ortho
• C07D 491/04 - Systèmes condensés en ortho
• C07D 495/04 - Systèmes condensés en ortho
• C07D 495/16 - Systèmes condensés en péri
• C07D 495/20 - Systèmes condensés en spiro
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
• A61P 25/16 - Antiparkinsoniens
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Produits et services

Diagnostic preparations for medical purposes; diagnostic reagents for medical use Providing medical information; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; pathological testing for diagnostic or treatment purposes.

Abrégé

According to the present invention, a syringe for cryopreservation of cells, a nucleic acid, or a protein comprising: a barrel having a spout and an opening and for containing cells, a nucleic acid, or a protein; a gasket slidably accommodated in the barrel; a plunger connected to the gasket; and a cap that seals the spout of the barrel, wherein the barrel is formed from a fluororesin, and the gasket is formed from a fluororesin or a polyethylene resin. The syringe is excellent in usability, durability, and safety.

Classes IPC  ?

• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• A61M 5/31 - Seringues Parties constitutives
• A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage

Abrégé

It is to provide a liquid for cryopreserving a cell that can effectively suppress cell death caused by freezing and thawing of a mammalian cell and that can effectively increase the proliferation ability of the mammalian cell after freezing and thawing, and a method for cryopreserving a mammalian cell using the liquid for cryopreserving a cell. A liquid comprising 2.5 to 8.75 (v/v) % propylene glycol is used as a liquid for cryopreserving a mammalian cell.

Classes IPC  ?

• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet

Abrégé

To provide a method for producing a sheet-like cell culture showing a three-layer structure including a cell layer of superficial cells, a cell layer of intermediate cells, and a cell layer of basal cells, in this order. Provided is a method for producing a sheet-like cell culture that includes culturing a progenitor cell population in a second compartment separated from a first compartment via a porous member to form a sheet-like cell culture in the second compartment. The sheet-like cell culture includes a cell layer of superficial cells derived from the progenitor cell population, a cell layer of intermediate cells derived from the progenitor cell population, and a cell layer of basal cells derived from the progenitor cell population, in this order. The first compartment holds an induction medium containing retinoic acid, bone morphogenetic protein (BMP), and fibroblast growth factor (FGF).

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• A01K 67/0271 - Vertébrés chimériques, p. ex. comprenant des cellules exogènes
• A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
• A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
• A61L 27/38 - Cellules animales
• A61L 27/40 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent
• A61P 13/10 - Médicaments pour le traitement des troubles du système urinaire de la vessie
• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables

Produits et services

Non-medicated skin serums; Beauty serums

Abrégé

The purpose of the present invention is to enable prescription of a gelled nutritional composition to which stricter sterilization conditions can be applied. This gelled nutritional composition contains a protein, a carbohydrate, a mineral, and a gelling agent, and has a viscosity of 6,500-18,000 mPa·s. The protein contains a collagen peptide together with a protein selected from the group consisting of milk-derived proteins and plant-derived proteins, whereby aggregation can be suppressed even under stricter sterilization conditions.

Classes IPC  ?

• A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
• A23L 29/256 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des agents gélifiants ou épaississants d'origine végétale à base d'algues, p. ex. alginates, agar-agar ou carraghénane

Abrégé

An object of the present invention is to provide a rubber composition that can improve reinforcement and heat resistance while also improving fuel efficiency, when carbon black and silica are blended with natural rubber, for example, in application in tires. The rubber composition contains a rubber component, a hydrazone compound, carbon black, silica, and 3-octanoylthio-1-propyltriethoxysilane, wherein natural rubber is present in an amount of 50 parts by mass or more in 100 parts by mass of the rubber component; per 100 parts by mass of the rubber component, the hydrazone compound is present in an amount of 0.1 parts by mass to 2 parts by mass, the carbon black is present in an amount of 15 parts by mass to 60 parts by mass, and the silica is present in an amount of 18 parts by mass to 80 parts by mass; and per 100 parts by mass of the silica, the 3-octanoylthio-1-propyltriethoxysilane is present in an amount of 3 parts by mass to 10 parts by mass.

Classes IPC  ?

• C08L 7/00 - Compositions contenant du caoutchouc naturel
• B60C 1/00 - Pneumatiques caractérisés par la composition chimique, la disposition ou le mélange physique de la composition
• C08K 3/04 - Carbone
• C08K 3/36 - Silice
• C08K 5/30 - HydrazonesSemicarbazones
• C08K 5/548 - Composés contenant du silicium contenant du soufre

Abrégé

Provided is a content processing method for determining a degree of priority of presentation of each of a plurality of contents, comprising: identifying the plurality of contents; receiving a first set including contents given positive evaluations and a second set including contents given negative evaluations from among the plurality of contents; extracting a first word set included in the first set and a second word set included in the second set; identifying a plurality of keywords including a plurality of positive keywords related to the first set and a plurality of negative keywords related to the second set according to a first evaluation criterion, the plurality of positive keywords being identified based on the first word set, the plurality of negative keywords being identified based on the second word set; giving weights to the plurality of keywords according to a second evaluation criterion so as to give a weight of zero or more to each of the plurality of positive keywords and give a weight of zero or less to each of the plurality of negative keywords; deriving a total for each of the plurality of contents by summing, over the plurality of keywords, a product of a frequency of appearance of each of the plurality of keywords and the given weight for the each of the plurality of keywords to obtain the total for each of the plurality of contents; and determining the degree of priority of presentation of each of the plurality of contents based on the total for the each of the plurality of contents.

Classes IPC  ?

• G06F 16/338 - Présentation des résultats des requêtes

Produits et services

(1) Prepared meals, namely, frozen pizza having non-dairy cheese substitute toppings; non-dairy food products, namely, cheese shreds, cheese slices, cheese blocks, cheese sticks, cheese spreads, yogurt, yogurt based snack food, non-dairy cheese substitutes; vegan cheese; frozen, prepared and packaged non-dairy meals, prepared meals primarily consisting of non-dairy foods. (2) Non-dairy food products, namely, salad dressings, pizza, frozen desserts, ice cream, ice cream bars, cakes, macaroni with cheese, cheese sauce, burritos, cheese based snack foods, snack crackers, cheese cake, cheese based snack foods.

Abrégé

The present invention provides a two-liquid mixture type infusion preparation in which precipitation is unlikely to occur even due to a change in composition upon addition of a calcium ion correction liquid. Provided as a solution is an infusion preparation which is for administration to a peripheral vein, which has two chambers that are separated by a partition that allows for communication, in which a first chamber infusion containing an amino acid is accommodated in a first chamber, and in which a second chamber infusion containing a sugar is accommodated in a second chamber, wherein a liquid mixture of the first chamber infusion and the second chamber infusion has (A) a pH of not more than 6.4 and (B) contains an organic acid in a total amount of not less than 3 mEq/L.

Classes IPC  ?

• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 9/08 - Solutions
• A61K 31/70 - Hydrates de carboneSucresLeurs dérivés
• A61K 47/02 - Composés inorganiques
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61P 7/08 - Substitut de plasmaSolutions de perfusionDyalisats ou hémodyalisatsMédicaments pour le traitement des troubles électrolytiques ou acido-basiques, p. ex. choc hypovolémique

Abrégé

Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5) Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5) Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5) wherein the crystal has peaks at diffraction angles 2θ(°) of 9.6±0.2, 19.1±0.2, and 21.2±0.2 in an X-ray powder diffraction pattern measured using Cukα characteristic X-rays.

Classes IPC  ?

• C07D 263/32 - Composés hétérocycliques contenant des cycles oxazole-1, 3 ou oxazole-1, 3 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle

Abrégé

The problem addressed is to provide an agent for preventing or treating steroid osteoporosis. The problem is solved by an agent for preventing or treating steroid osteoporosis that contains a Piezo1 and/or an Hes1 enhancer.

Classes IPC  ?

• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
• A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
• A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget de l'ostéoporose
• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes

Abrégé

The purpose of the present invention is to provide a rubber composition having, in a vulcanized rubber, superior low heat generation properties (low fuel consumption properties). The rubber composition comprises a rubber component, and a compound represented by formula (1) and/or a salt thereof. Also provided is a heat generation reduction agent for rubber.

Classes IPC  ?

• C08L 101/00 - Compositions contenant des composés macromoléculaires non spécifiés
• B60C 1/00 - Pneumatiques caractérisés par la composition chimique, la disposition ou le mélange physique de la composition
• C08K 3/04 - Carbone
• C08K 3/013 - Charges, pigments ou agents de renforcement
• C08K 5/34 - Composés hétérocycliques comportant de l'azote dans le cycle

Abrégé

An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.

Classes IPC  ?

• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/10 - DispersionsÉmulsions
• A61K 47/02 - Composés inorganiques
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
• A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères

Abrégé

The invention provides a method for producing a sulfated polysaccharide by generating a sulfated polysaccharide by incorporating, in a reaction solution in the presence of ATP or an ATP source, a sulfate ion source, and N-sulfoheparosan, a transformant (a) of a bacterium of the genus Corynebacterium, comprising at least a gene encoding an ATP sulfurylase and a gene encoding an APS kinase, and at least one selected from a transformant (b) of a microorganism belonging to prokaryotes, comprising at least a gene encoding a C5-epimerase, a transformant (c) of a microorganism belonging to prokaryotes, comprising at least a gene encoding a 2-O-sulfotransferase, a transformant (d) of a microorganism belonging to prokaryotes, comprising at least a gene encoding a 6-O-sulfotransferase, and a transformant (e) of a microorganism belonging to prokaryotes, comprising at least a gene encoding a 3-O-sulfotransferase.

Classes IPC  ?

• C12P 19/26 - Préparation d'hydrates de carbone contenant de l'azote
• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
• C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques

Abrégé

The present invention relates to a composition for improving the function of the liver, said composition containing a Japanese horseradish (wasabi) extract obtained using an organic solvent.

Classes IPC  ?

• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques

Produits et services

Pharmaceutical preparations for the treatment of central nervous system diseases and disorders, containing electronic chips which transmit information about drug ingestion by the patient Computer application software for mobile phones, tablets, portable electronic devices and handheld computers for use in collecting and storing patient data and medical information including drug ingestion information, pulse, heart rate, respiratory rate, body temperature, electric pressure in the body, human motion, human position or sleeping condition from a sensor attached to the patient's body. Sensor patches attached to the patient's body for use in measuring, collecting and storing patient data and medical information including drug ingestion information, pulse, heart rate, respiratory rate, body temperature, electric pressure in the body, human motion, human position or sleeping condition.

Abrégé

The invention relates to methods of synthesizing 2′-deoxy-2′,2′-difluorotetrahydrouridine with increased purity and uniform particle size distribution. In particular, methods of the invention include crystallization and isolation procedures rendering synthetic reaction intermediates. The invention further includes compositions comprising the final compound in highly pure form, including lower number of impurities and lower levels of individual and total impurities.

Classes IPC  ?

• C07H 19/06 - Radicaux pyrimidine
• C07H 1/00 - Procédés de préparation des dérivés du sucre

Abrégé

The present disclosure relates to novel crystalline forms of sulfonamide compounds, pharmaceutical compositions containing the crystalline form compounds and methods of preparing and using the same.

Classes IPC  ?

• C07D 271/113 - Oxadiazoles-1, 3, 4Oxadiazoles-1, 3, 4 hydrogénés avec des atomes d'oxygène, de soufre ou d'azote, liés directement aux atomes de carbone du cycle, les atomes d'azote ne faisant pas partie d'un radical nitro
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

Provided is a liquid crystal polymer composition that, in relation to sliding between a liquid crystal polymer molded body thereof and a metal material, is capable of reducing the friction coefficient to a low level both at an early stage of the sliding and after the sliding has been repeated multiple times.　This liquid crystal polymer composition comprises a liquid crystal polymer (A), a first inorganic filler (B1), a second inorganic filler (B2), and a solid lubricant (C). A treatment layer composed of a hydrophilic surface treatment agent is provided on the surface of the first inorganic filler (B1), and a treatment layer composed of a hydrophobic surface treatment agent is provided on the surface of the second inorganic filler (B2).

Classes IPC  ?

• C08L 101/12 - Compositions contenant des composés macromoléculaires non spécifiés caractérisées par des propriétés physiques, p. ex. anisotropie, viscosité ou conductivité électrique
• C08K 3/01 - Emploi de substances inorganiques en tant qu'adjuvants caractérisées par leur fonction
• C08K 3/30 - Composés contenant du soufre, du sélénium ou du tellure
• C08K 9/00 - Emploi d'ingrédients prétraités
• C08L 101/00 - Compositions contenant des composés macromoléculaires non spécifiés

Produits et services

(1) Pharmaceutical preparations for the treatment of tumor; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; tumor suppressing agents; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders; pharmaceutical preparations for the treatment of muscular diseases and disorders; pharmaceutical preparations for the treatment of urological diseases and disorders; pharmaceutical preparations for the treatment of digestive diseases and disorders; pharmaceutical preparations for the treatment of gastroesophageal reflux diseases and disorders; pharmaceutical preparations for the treatment of hepatic diseases and disorders; pharmaceutical preparations for the treatment of renal diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immune diseases and disorders; immunomodulators; immunosuppressive agents; pharmaceutical preparations for the treatment of diseases of the central and peripheral nervous system; pharmaceutical preparations for the treatment of rheumatoid arthritis; pharmaceutical preparations for the treatment of diseases of the blood; pharmaceutical preparations for treating hematological disorders; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for use in chemotherapy; anti-emetic medicines; pharmaceutical preparations for the treatment of pain; analgesic preparations; antiphlogistic preparations; chemical preparations for pharmaceutical purposes; diagnostic reagents for medical purposes in the field of oncology.

Produits et services

(1) Pharmaceutical preparations for the treatment of tumor; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; tumor suppressing agents; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders; pharmaceutical preparations for the treatment of muscular diseases and disorders; pharmaceutical preparations for the treatment of urological diseases and disorders; pharmaceutical preparations for the treatment of digestive diseases and disorders; pharmaceutical preparations for the treatment of gastroesophageal reflux diseases and disorders; pharmaceutical preparations for the treatment of hepatic diseases and disorders; pharmaceutical preparations for the treatment of renal diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immune diseases and disorders; immunomodulators; immunosuppressive agents; pharmaceutical preparations for the treatment of diseases of the central and peripheral nervous system; pharmaceutical preparations for the treatment of rheumatoid arthritis; pharmaceutical preparations for the treatment of diseases of the blood; pharmaceutical preparations for treating hematological disorders; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for use in chemotherapy; anti-emetic medicines; pharmaceutical preparations for the treatment of pain; analgesic preparations; antiphlogistic preparations; chemical preparations for pharmaceutical purposes; diagnostic reagents for medical purposes in the field of oncology.

Produits et services

(1) Pharmaceutical preparations for the treatment of tumor; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; tumor suppressing agents; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders; pharmaceutical preparations for the treatment of muscular diseases and disorders; pharmaceutical preparations for the treatment of urological diseases and disorders; pharmaceutical preparations for the treatment of digestive diseases and disorders; pharmaceutical preparations for the treatment of gastroesophageal reflux diseases and disorders; pharmaceutical preparations for the treatment of hepatic diseases and disorders; pharmaceutical preparations for the treatment of renal diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immune diseases and disorders; immunomodulators; immunosuppressive agents; pharmaceutical preparations for the treatment of diseases of the central and peripheral nervous system; pharmaceutical preparations for the treatment of rheumatoid arthritis; pharmaceutical preparations for the treatment of diseases of the blood; pharmaceutical preparations for treating hematological disorders; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for use in chemotherapy; anti-emetic medicines; pharmaceutical preparations for the treatment of pain; analgesic preparations; antiphlogistic preparations; chemical preparations for pharmaceutical purposes; diagnostic reagents for medical purposes in the field of oncology.

Abrégé

Provided is a heat-resistant coated article excellent in both heat resistance and water resistance.　A heat-resistant coated article 1 comprises: a base material 2; a first coating film 3 provided on a surface 2a of the base material 2; and a second coating film 4 provided on the first coating film 3. The first coating film 3 is a heat-cured product of a composition containing an alkali metal silicate and inorganic particles. The second coating film 4 is a cured product formed by an alkali metal silicate and an acidic curing agent.

Classes IPC  ?

• B32B 9/00 - Produits stratifiés composés essentiellement d'une substance particulière non couverte par les groupes
• B05D 1/38 - Applications successives de liquides ou d'autres matériaux fluides, p. ex. sans traitement intermédiaire avec traitement intermédiaire
• B05D 3/02 - Traitement préalable des surfaces sur lesquelles des liquides ou d'autres matériaux fluides doivent être appliquésTraitement ultérieur des revêtements appliqués, p. ex. traitement intermédiaire d'un revêtement déjà appliqué, pour préparer les applications ultérieures de liquides ou d'autres matériaux fluides par cuisson
• B05D 5/00 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces pour obtenir des effets, finis ou des structures de surface particuliers
• B05D 7/24 - Procédés, autres que le flocage, spécialement adaptés pour appliquer des liquides ou d'autres matériaux fluides, à des surfaces particulières, ou pour appliquer des liquides ou d'autres matériaux fluides particuliers pour appliquer des liquides ou d'autres matériaux fluides particuliers
• B32B 15/04 - Produits stratifiés composés essentiellement de métal comprenant un métal comme seul composant ou comme composant principal d'une couche adjacente à une autre couche d'une substance spécifique
• C09D 1/02 - Compositions de revêtement, p. ex. peintures, vernis ou vernis-laques, à base de substances inorganiques silicates de métaux alcalins
• C09D 7/61 - Adjuvants non macromoléculaires inorganiques

Abrégé

In order to provide a novel cancer treatment method using a FTD-TPI combination drug that exhibits markedly excellent anti-tumor effects with fewer side effects, the present invention provides an anti-tumor agent characterized in that the FTD.TPI combination drug and a taxane compound are administered in combination.

Classes IPC  ?

• A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p. ex. uridine, acide uridylique, thymidine, zidovudine
• A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
• A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine

Produits et services

Pharmaceutical preparations for the treatment of tumor; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; tumor suppressing agents; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders; pharmaceutical preparations for the treatment of muscular diseases and disorders; pharmaceutical preparations for the treatment of urological diseases and disorders; pharmaceutical preparations for the treatment of digestive diseases and disorders; pharmaceutical preparations for the treatment of gastroesophageal reflux diseases and disorders; pharmaceutical preparations for the treatment of hepatic diseases and disorders; pharmaceutical preparations for the treatment of renal diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immune diseases and disorders; immunomodulators; immunosuppressive agents; pharmaceutical preparations for the treatment of diseases of the central and peripheral nervous system; pharmaceutical preparations for the treatment of rheumatoid arthritis; pharmaceutical preparations for the treatment of diseases of the blood; pharmaceutical preparations for treating hematological disorders; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for use in chemotherapy; anti-emetic medicines; pharmaceutical preparations for the treatment of pain; analgesic preparations; antiphlogistic preparations; pharmaceutical preparations; chemical preparations for pharmaceutical purposes; chemical reagents for medical purposes in the field of oncology.

Produits et services

Pharmaceutical preparations for the treatment of tumor; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; tumor suppressing agents; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders; pharmaceutical preparations for the treatment of muscular diseases and disorders; pharmaceutical preparations for the treatment of urological diseases and disorders; pharmaceutical preparations for the treatment of digestive diseases and disorders; pharmaceutical preparations for the treatment of gastroesophageal reflux diseases and disorders; pharmaceutical preparations for the treatment of hepatic diseases and disorders; pharmaceutical preparations for the treatment of renal diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immune diseases and disorders; immunomodulators; immunosuppressive agents; pharmaceutical preparations for the treatment of diseases of the central and peripheral nervous system; pharmaceutical preparations for the treatment of rheumatoid arthritis; pharmaceutical preparations for the treatment of diseases of the blood; pharmaceutical preparations for treating hematological disorders; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for use in chemotherapy; anti-emetic medicines; pharmaceutical preparations for the treatment of pain; analgesic preparations; antiphlogistic preparations; pharmaceutical preparations; chemical preparations for pharmaceutical purposes; chemical reagents for medical purposes in the field of oncology.

Abrégé

The present invention provides a brain-migrating anti-tumor agent that exhibits brain migration ability and EGFR inhibitory activity. One embodiment of the present invention provides a brain-migrating anti-tumor agent comprising, as an active ingredient, N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl) bicyclo[2.2.1]heptan-1-yl)-5-methylpyrazine-2-carboxamide or a salt thereof.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61P 35/00 - Agents anticancéreux
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Produits et services

Pharmaceutical preparations for the treatment of tumor; pharmaceutical preparations for the treatment of cancer; chemical reagents for medical purposes in the field of oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders; pharmaceutical preparations for the treatment of muscular diseases and disorders; pharmaceutical preparations for the treatment of urological diseases and disorders; pharmaceutical preparations for the treatment of digestive diseases and disorders; pharmaceutical preparations for the treatment of gastroesophageal reflux diseases and disorders; pharmaceutical preparations for the treatment of hepatic diseases and disorders; pharmaceutical preparations for the treatment of renal diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of diseases of the central and peripheral nervous system; pharmaceutical preparations for the treatment of rheumatoid arthritis; pharmaceutical preparations for the treatment of diseases of the blood; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for use in chemotherapy; anti-emetic medicines; pharmaceutical preparations for the treatment of pain; analgesic preparations; antiphlogistic preparations, namely, pharmaceutical preparations for the treatment of inflammation

Produits et services

Breath freshening preparations for personal hygiene; soap; cosmetic soaps; facial soaps; facial washes (soaps); dentifrices; serums for cosmetic purposes; non-medicated skin serums; beauty serums; sunscreen serums; cotton swabs for cosmetic purposes; cotton wool for cosmetic purposes; perfumery, other than perfumes for personal use; essential oils; incense; false nails; false eyelashes. Pharmaceutical preparations; serums for medical purposes; pharmaceutical agents for epidermis; pharmaceutical preparations for skin care; pharmaceutical preparations for treating sunburn; medicated sunburn ointment and lotions; medicated toiletry preparations; medicated cosmetics; medicated skin care preparations; medicated skin creams; medicated skin lotions; medicated lip care preparations; medicated bath preparations; medicated soap; dietary supplements for humans; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; food for babies.

Abrégé

Provided is a computer program, an information processing device, and a method that are used to estimate a health state of a target user based on a history of behaviors executed by the target user, and have at least partially improved performance. Provided is a computer program, an information processing device, and a method that are used to estimate a health state of a target user based on a history of behaviors executed by the target user, and have at least partially improved performance. According to one embodiment, a computer program can cause, by being executed at least one processor, the at least one processor to function to: acquire target behavior data for identifying a history of behavior executed by a target user; and output, from an estimation model generated by executing supervised learning, target sleep state data for identifying a sleep state of the target user, the target sleep state data including at least one of target property data for identifying a sleep property of the target user, target rhythm data for identifying a sleep rhythm of the target user, target time data for identifying a sleep time of the target user, and target category data for identifying a sleep category to which the target user belongs, by inputting the target behavior data to the estimation model.

Classes IPC  ?

• G16H 20/60 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant le contrôle de l’alimentation, p. ex. les régimes
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux

Abrégé

The present disclosure relates generally to use of a compound of formula (I), also named ASTX660 in combination therapies for treating cancer, in particular leukemia.

Classes IPC  ?

• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
• A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie

Abrégé

To provide a member for cutting work that is excellent in cutting workability and can suppress the occurrence of burrs when performing cutting work such as scraping, cutting, or drilling a hole using a mechanical tool.　The member for cutting work is made from a molded body of a resin composition containing a thermoplastic resin (A) and a reinforcing material (B) and is characterized in that the thermoplastic resin (A) is a crystalline thermoplastic resin, the reinforcing material (B) is an inorganic reinforcing material having a Mohs hardness of 5 or less, and a cutting property parameter defined by formula (1) from the fracture toughness K1c and flexural modulus of the member for cutting work is 20 m1/2to 180 m1/2.　Cutting parameter=(fracture toughness K1c/flexural modulus)×105 … Formula (1)

Classes IPC  ?

• C08J 5/00 - Fabrication d'objets ou de matériaux façonnés contenant des substances macromoléculaires
• C08K 3/013 - Charges, pigments ou agents de renforcement
• C08L 101/00 - Compositions contenant des composés macromoléculaires non spécifiés

Abrégé

Provided is a member for machining which, when machined by shaving, cutting, or drilling, for example, using a mechanical tool, exhibits excellent machinability and suppresses generation of burrs.　The member for machining is composed of a molded object of a resin composition containing a thermoplastic resin (A) and a reinforcing material (B), and is characterized in that: the thermoplastic resin (A) is an amorphous thermoplastic resin; the reinforcing material (B) is an inorganic reinforcing material having a Mohs hardness of 5 or less; and a machinability parameter defined by equation (1) from the fracture toughness K1c and flexural modulus of the member for machining is 15 m1/2to 100 m1/2.　Equation (1): Machinability parameter = (fracture toughness K1c)/(flexural modulus)×105

Classes IPC  ?

• C08J 5/00 - Fabrication d'objets ou de matériaux façonnés contenant des substances macromoléculaires
• C08K 3/013 - Charges, pigments ou agents de renforcement
• C08L 101/00 - Compositions contenant des composés macromoléculaires non spécifiés

Produits et services

Medical device systems for use in renal denervation and other forms of neuromodulation of the autonomic nervous system, consisting of guiding catheters, medical guidewires, medical introducers; Medical devices, medical device systems consisting of medical devices, medical apparatus, and medical instruments, all for treating heart failure, chronic kidney disease, end stage renal disease, myocardial infarction, anxiety, contrast nephropathy, diabetes, metabolic disorder and insulin resistance; energy emitting catheter-based systems consisting of medical devices and devices for medical procedures in the nature of neuromodulation and denervation of the autonomic nervous system for use in treating a variety of medical conditions, also consisting of guiding catheters, medical guidewires, medical introducers

Abrégé

The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.

Classes IPC  ?

• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone
• A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
• A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
• A61K 31/15 - Oximes (C=N-O-)Hydrazines ( N-N)Hydrazones (N-N=)
• A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
• A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
• A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
• A61K 31/4525 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'oxygène comme hétéro-atome du cycle
• A61K 31/5513 - 1,4-Benzodiazépines, p. ex. diazépam
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

An oil-in-water emulsion composition that has zinc chloride as an active component and provides excellent separation inhibiting properties and/or drug release properties. The oil-in-water emulsion composition comprises: (A) not less than 30 wt % of zinc chloride; (B) an oily base selected from the group consisting of hydrocarbon oils and higher alcohols; (C) a non-ionic surfactant; and (D) an aqueous base selected from the group consisting of water and polyalcohols. The content of (B) with respect to 100 parts by weight of the components (B) and (C) combined is not less than 52 parts by weight. The content of (B) with respect to 100 parts by weight of the component (B) and the component (D) combined is not less than 11.7 parts by weight. The oil-in-water emulsion composition has excellent separation inhibiting properties. When the component (D) is water and polyethylene glycol, the oil-in-water emulsion composition has excellent drug release properties.

Classes IPC  ?

• A61K 9/107 - Émulsions
• A61K 33/30 - ZincSes composés
• A61K 47/02 - Composés inorganiques
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE

Abrégé

Embodiments of the present invention provide solid oral dosage forms that upon daily administration to a subject provide plasma levels of decitabine with a 5-day AUC for decitabine that is equivalent to the 5-day AUC for a daily IV dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided according to embodiments of the present invention are solid oral dosage forms wherein upon daily administration to a subject provides a pharmacodynamic effect that is equivalent to the pharmacodynamic effect for a daily intravenous dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided are methods of treatment using a solid oral dosage form according to an embodiment of the invention.

Classes IPC  ?

• A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
• A61K 31/7016 - Disaccharides, p. ex. lactose, lactulose
• A61K 31/717 - Celluloses

Abrégé

A viscoelastic composition for securing the field of view of an endoscope, the viscoelastic composition comprising a thickening substance and water and having a shear storage modulus G′ of 0.7 Pa or more, and a method for securing the field of view of an endoscope, the method comprising feeding the viscoelastic composition from a proximal part of the endoscope, through a channel, into a distal part of the endoscope.

Classes IPC  ?

• A61L 31/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
• A61B 1/012 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments caractérisés par les conduits internes ou par leurs accessoires
• A61L 31/04 - Matériaux macromoléculaires

Abrégé

An object of the present disclosure is to provide a crystalline form of 3-(15-methoxypentadecyl)-2, 4, 4-trimethylcyclohex-2-en-1-one, the crystalline form having excellent stability and being preferable in terms of production. The present disclosure provides a crystalline form having characteristic peaks at diffraction angles) (2θ+0.2° of 7.0°, 14.0°, 17.5°, 19.5°, 21.0°, 23.7°, and 24.8° in a powder X-ray diffraction spectrum (CuKα).

Classes IPC  ?

• C07C 49/753 - Composés non saturés comportant un groupe cétone faisant partie d'un cycle contenant des groupes éther, des groupes , des groupes ou des groupes
• A61K 9/08 - Solutions
• A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
• A61K 47/38 - CelluloseSes dérivés

Produits et services

Education and training in the use and operation of medical and surgical equipment, apparatus and appliances and instruments, and consultation relating to the selection and purchase thereof and use in medical care, medical therapy and surgery Medical research services; providing an online computer database, namely, a repository of information in the field of medical data and healthcare information accessible to healthcare providers, including clinical studies, case studies, peer-reviewed journal articles and references Providing medical information, consultancy and advisory services; professional consultation in the field of medical and surgical equipment, apparatus, appliance and instruments; consultation on medical care, medical therapy and surgery; consultation services, namely, providing medical information to medical professionals to assist in the diagnosis and treatment of patients; medical consultation with physicians regarding the use of medical apparatus for treatment of patients; technical consultation in the field of medical and surgical equipment, apparatus, appliances and instruments, namely, consultation regarding the selection and purchase thereof, and the use in providing medical care, medical therapy and surgery; providing a patient support program, namely, providing medical information to patients evaluating therapeutic treatment options; providing medical information to patients in the field of surgery preparation; maintaining patient medical records and files in preparation for surgery; providing medical advisory and consultancy services concerning medical coding and medical reimbursement; providing online medical evaluation services, namely, functional assessment program for patients who are about to receive medical treatment services for purposes of guiding treatment and assessing program effectiveness; home health care services in the nature of interactive medical care monitoring for patients; managed healthcare services, namely, providing disease management programs to others; providing an on-line computer database, namely, a repository of information in the field of medical and healthcare information, including clinical studies, case studies, peer-reviewed journal articles, and references, accessible to healthcare providers; providing a website featuring medical information via monitoring devices for purposes of monitoring and diagnosing medical conditions by medical professionals

Produits et services

Soap; cosmetic soaps; dentifrices; toilet water; lotions for cosmetic purposes; skin lotion; hair lotion; body lotion; wave-set lotions; perfumery, other than perfumes for personal use; incense; false nails; false eyelashes.

Abrégé

According to the present invention, a syringe comprising a barrel having a spout and an opening; a gasket slidably accommodated in the barrel; a plunger connected to the gasket; and a cap that seals the spout of the barrel, wherein the opening of the barrel is sealed only with the gasket. The syringe is excellent in usability, durability, and safety.

Classes IPC  ?

• A61J 1/05 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques pour recueillir, stocker ou administrer du sang, du plasma ou des liquides à usage médical

Abrégé

Provided are a novel cancer treatment method and immunostimulant which exhibit a remarkably excellent antitumor effect with little side effects. An antitumor agent and an immunostimulant include an azabicyclo compound and an immune checkpoint molecule regulator which are administered in combination.

Classes IPC  ?

• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• A61P 37/04 - Immunostimulants

Abrégé

Provided is a method of treating malignant tumor by an azabicyclic compound, particularly, with eye disorder reduced. The present invention provides a method for treating malignant tumor, comprising administering an effective amount of 3-ethyl-4-[3-(1-methylethyl)-4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-1H-pyrazolo[3,4-b]pyridin-1-yl]benzamide (compound 1) or a salt thereof to a patient in need thereof according to a dosing regimen, wherein the dosing regimen comprises administering the compound 1 or the salt thereof at a dose from 40 mg/body/day to 240 mg/body/day in terms of the amount of the compound 1 for consecutive days, and then providing a withdrawal period of at least 2 days.

Classes IPC  ?

• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 35/00 - Agents anticancéreux

Produits et services

Maintaining patient medical records and files in preparation for surgery. Education, namely, training in the use and operation of medical and surgical equipment, apparatus and appliances and instruments, and consultation relating to the selection and use thereof to provide medical care, medical therapy and surgery. Medical research services; providing an online computer database, namely, a repository of information in the field of medical clinical studies and medical research via medical case studies, peer-reviewed medical journal articles and medical references (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations). Providing medical information, consultancy and advisory services; professional consultation in the field of the use of medical and surgical equipment, apparatus, appliance and instruments; consultation on medical care, medical therapy and surgery; consultation services, namely, providing medical information to medical professionals to assist in the diagnosis and treatment of patients; medical consultation with physicians regarding the use of medical apparatus for treatment of patients; technical consultation in the field of medical and surgical equipment, apparatus, appliances and instruments, namely, consultation regarding their use in providing medical care, medical therapy and surgery; providing a patient support program, namely, providing medical information to patients evaluating therapeutic treatment options; providing medical information to patients in the field of surgery preparation; providing an on-line computer database, namely, a repository of information in the field of medical information and healthcare information accessible to healthcare providers including case studies, peer-reviewed journal articles and references (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); providing online medical evaluation services, namely, functional assessment program for patients who are about to receive medical treatment services for purposes of guiding treatment and assessing program effectiveness; home health care services in the nature of interactive medical care monitoring for patients; managed healthcare services, namely, providing disease management programs to others; consultation relating to the use of medical and surgical equipment, apparatus and appliances and instruments in medical care, medical therapy and surgery; providing an internet website for medical professionals and patients featuring medical information from remote locations via electronic patient monitoring devices that feed information to the website that can be accessed in real-time by medical professionals for purposes of monitoring and diagnosing medical conditions (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations).

Abrégé

The present disclosure relates to processes for preparing synthetic intermediates for the synthesis of isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity.

Classes IPC  ?

• C07D 309/06 - Radicaux substitués par des atomes d'oxygène
• C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07F 7/18 - Composés comportant une ou plusieurs liaisons C—Si ainsi qu'une ou plusieurs liaisons C—O—Si

Abrégé

Provided is a novel chimeric antigen receptor. This chimeric antigen receptor includes an scFv region having such a structure that the C-terminus of a heavy-chain variable region and the N-terminus of a light-chain variable region are linked to each other through a linker, wherein: the heavy-chain variable region includes a heavy-chain CDR1 having the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 having the amino acid sequence represented by SEQ ID NO: 2, and/or a heavy-chain CDR3 having the amino acid sequence represented by SEQ ID NO: 3, and/or the light-chain variable region includes a light-chain CDR1 having the amino acid sequence represented by SEQ ID NO: 5, a light-chain CDR2 having the amino acid sequence represented by SEQ ID NO: 6, and/or a light-chain CDR3 having the amino acid sequence represented by SEQ ID NO: 7; and the number of amino acid residues constituting the linker is 15-50.

Classes IPC  ?

• C07K 19/00 - Peptides hybrides
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61P 35/00 - Agents anticancéreux
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/13 - Immunoglobulines
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Abrégé

This invention provides an antibody that binds specifically to sulfated glycosaminoglycan (sGAG) in a pH-dependent manner. The antibody that binds specifically to sulfated glycosaminoglycan is at least one antibody selected from the group consisting of (1) to (3): (1) an antibody comprising a heavy chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 1, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 2, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 3 and a light chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 4, CDR2 consisting of the amino acid sequence represented by LGS, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 6; (2) an antibody comprising a heavy chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 7, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 8, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 9 and a light chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 10, CDR2 consisting of the amino acid sequence represented by AAS, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 12; and (3) an antibody comprising a heavy chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 13, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 14, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 15 and a light chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 16, CDR2 consisting of the amino acid sequence represented by WAS, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 18.

Classes IPC  ?

• C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
• A61P 35/00 - Agents anticancéreux

Abrégé

Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent (s). Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent (s).

Classes IPC  ?

• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
• A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
• A61K 33/243 - PlatineSes composés
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

The present disclosure relates to pharmaceutical compositions comprising a solid dispersion comprising a compound of Formula (I): (I), or a pharmaceutically acceptable salt thereof, as well as methods of treatment.

Classes IPC  ?

• A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

Provided is a binder composition for an all-solid-state battery in which an inorganic binder component is used and which enables the formation of a solid electrolyte layer capable of allowing an all-solid-state battery to exert excellent ionic conductivity. A binder composition for an all-solid-state battery is used in formation of an all-solid-state battery and contains a flaky metal acid compound, wherein the flaky metal acid compound is composed of: a flaky metal acid; and a basic compound and/or a lithium salt.

Classes IPC  ?

• H01M 10/0562 - Matériaux solides
• C01G 23/047 - Dioxyde de titane
• H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium

Produits et services

(1) Pharmaceutical preparations for the treatment of tumor; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; tumor suppressing agents; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders; pharmaceutical preparations for the treatment of muscular diseases and disorders; pharmaceutical preparations for the treatment of urological diseases and disorders; pharmaceutical preparations for the treatment of digestive diseases and disorders; pharmaceutical preparations for the treatment of gastroesophageal reflux diseases and disorders; pharmaceutical preparations for the treatment of hepatic diseases and disorders; pharmaceutical preparations for the treatment of renal diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immune diseases and disorders; pharmaceutical preparations for the treatment of diseases of the central and peripheral nervous system; pharmaceutical preparations for the treatment of rheumatoid arthritis; pharmaceutical preparations for the treatment of diseases of the blood; pharmaceutical preparations for treating hematological disorders; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for use in chemotherapy; anti-emetic medicines; pharmaceutical preparations for the treatment of pain; analgesic preparations; antiphlogistic preparations; chemical preparations for pharmaceutical purposes; diagnostic reagents for medical purposes in the field of oncology.

Abrégé

A plant-based food product is provided with improved properties is provided. The plant-based food product comprises a partially hydrolyzed and fermented vegetable protein, a viscosity modifier and a vegetable oil. A method of making the plant-based food product is also provided.

Classes IPC  ?

• A23C 20/00 - Succédanés du fromage
• A23C 20/02 - Succédanés du fromage ne contenant ni constituants du lait, ni caséinate, ni lactose, en tant que sources de matières grasses, de protéines ou d'hydrates de carbone
• A23J 3/14 - Protéines végétales
• A23L 33/18 - PeptidesHydrolysats de protéines
• A23L 33/185 - Protéines d’origine végétale